<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35552463</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.</ArticleTitle>
        <Pagination>
          <StartPage>7808</StartPage>
          <MedlinePgn>7808</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">7808</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-11748-x</ELocationID>
        <Abstract>
          <AbstractText>Bacille Calmette-Guérin (BCG), the only currently licenced tuberculosis vaccine, may exert beneficial non-specific effects (NSE) in reducing infant mortality. We conducted a randomised controlled clinical study in healthy UK adults to evaluate potential NSE using functional in-vitro growth inhibition assays (GIAs) as a surrogate of protection from four bacteria implicated in infant mortality. Volunteers were randomised to receive BCG intradermally (n = 27) or to be unvaccinated (n = 8) and were followed up for 84 days; laboratory staff were blinded until completion of the final visit. Using GIAs based on peripheral blood mononuclear cells, we observed a significant reduction in the growth of the Gram-negative bacteria Escherichia coli and Klebsiella pneumonia following BCG vaccination, but no effect for the Gram-positive bacteria Staphylococcus aureus and Streptococcus agalactiae. There was a modest association between S. aureus nasal carriage and growth of S. aureus in the GIA. Our findings support a causal link between BCG vaccination and improved ability to control growth of heterologous bacteria. Unbiased assays such as GIAs are potentially useful tools for the assessment of non-specific as well as specific effects of TB vaccines. This study was funded by the Bill and Melinda Gates Foundation and registered with ClinicalTrials.gov (NCT02380508, 05/03/2015; completed).</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wilkie</LastName>
            <ForeName>Morven</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tanner</LastName>
            <ForeName>Rachel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK. rachel.tanner@ndm.ox.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wright</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez Ramon</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beglov</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and British Heart Foundation Centre of Research Excellence Oxford, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riste</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham, B9 5SS, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Infection and Tropical Medicine, North Manchester General Hospital, Manchester, M8 5RB, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marshall</LastName>
            <ForeName>Julia L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harris</LastName>
            <ForeName>Stephanie A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bettencourt</LastName>
            <ForeName>Paulo J G</ForeName>
            <Initials>PJG</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine and Center for Interdisciplinary Research in Health, Catholic University of Portugal, 1649-023, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamidi</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chelsea and Westminster Hospital, London, SW10 9NH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Diemen</LastName>
            <ForeName>Pauline M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Animal and Plant Health Agency (APHA), Virology, APHA-Weybridge, New Haw, Addlestone, KT15 3NB, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moss</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham, B9 5SS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Satti</LastName>
            <ForeName>Iman</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wyllie</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McShane</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK. helen.mcshane@ndm.ox.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02380508</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D032581">Tuberculosis Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001500" MajorTopicYN="Y">BCG Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032581" MajorTopicYN="Y">Tuberculosis Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>14</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35552463</ArticleId>
        <ArticleId IdType="pmc">PMC9096342</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-11748-x</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-11748-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 1993;22:1154–1158. doi: 10.1093/ije/22.6.1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ije/22.6.1154</ArticleId>
            <ArticleId IdType="pubmed">8144299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346:1339–1345. doi: 10.1016/S0140-6736(95)92348-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(95)92348-9</ArticleId>
            <ArticleId IdType="pubmed">7475776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uthayakumar D, et al.  Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations. Front. Immunol. 2018;9:2869. doi: 10.3389/fimmu.2018.02869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02869</ArticleId>
            <ArticleId IdType="pmc">PMC6288394</ArticleId>
            <ArticleId IdType="pubmed">30564249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth A, et al.  Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr. Infect. Dis. J. 2004;23:544–550. doi: 10.1097/01.inf.0000129693.81082.a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.inf.0000129693.81082.a0</ArticleId>
            <ArticleId IdType="pubmed">15194836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirve S, et al.  Non-specific and sex-differential effects of vaccinations on child survival in rural western India. Vaccine. 2012;30:7300–7308. doi: 10.1016/j.vaccine.2012.09.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2012.09.035</ArticleId>
            <ArticleId IdType="pubmed">23022401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth A, et al.  BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int. J. Epidemiol. 2005;34:540–547. doi: 10.1093/ije/dyh392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ije/dyh392</ArticleId>
            <ArticleId IdType="pubmed">15659474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garly ML, et al.  BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine. 2003;21:2782–2790. doi: 10.1016/S0264-410X(03)00181-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0264-410X(03)00181-6</ArticleId>
            <ArticleId IdType="pubmed">12798618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ. 2000;321:1435–1438. doi: 10.1136/bmj.321.7274.1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.321.7274.1435</ArticleId>
            <ArticleId IdType="pmc">PMC27544</ArticleId>
            <ArticleId IdType="pubmed">11110734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaby P, et al.  Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 2011;204:245–252. doi: 10.1093/infdis/jir240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jir240</ArticleId>
            <ArticleId IdType="pubmed">21673035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskär T, Sommerfelt H. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health. 2015;15:175. doi: 10.1186/s12889-015-1497-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12889-015-1497-8</ArticleId>
            <ArticleId IdType="pmc">PMC4342809</ArticleId>
            <ArticleId IdType="pubmed">25886062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prentice S, et al.  BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect. Dis. 2021 doi: 10.1016/s1473-3099(20)30653-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1473-3099(20)30653-8</ArticleId>
            <ArticleId IdType="pmc">PMC8222005</ArticleId>
            <ArticleId IdType="pubmed">33609457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemes E, et al.  Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 2018;379:138–149. doi: 10.1056/NEJMoa1714021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1714021</ArticleId>
            <ArticleId IdType="pmc">PMC5937161</ArticleId>
            <ArticleId IdType="pubmed">29996082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stensballe LG, et al.  Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls: community based case–control study. Vaccine. 2005;23:1251–1257. doi: 10.1016/j.vaccine.2004.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2004.09.006</ArticleId>
            <ArticleId IdType="pubmed">15652667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth A, et al.  Tuberculin reaction, BCG scar, and lower female mortality. Epidemiology. 2006;17:562–568. doi: 10.1097/01.ede.0000231546.14749.ab.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.ede.0000231546.14749.ab</ArticleId>
            <ArticleId IdType="pubmed">16878042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaby P, Jensen H, Walraven G. Age-specific changes in the female-male mortality ratio related to the pattern of vaccinations: an observational study from rural Gambia. Vaccine. 2006;24:4701–4708. doi: 10.1016/j.vaccine.2006.03.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2006.03.038</ArticleId>
            <ArticleId IdType="pubmed">16621182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaby P, et al.  Sex differential effects of routine immunizations and childhood survival in rural Malawi. Pediatr. Infect. Dis. J. 2006;25:721–727. doi: 10.1097/01.inf.0000227829.64686.ae.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.inf.0000227829.64686.ae</ArticleId>
            <ArticleId IdType="pubmed">16874172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins, J. P. T., Soares-Weiser, K. &amp; Reingold, A. (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, et al.  Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170. doi: 10.1136/bmj.i5170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.i5170</ArticleId>
            <ArticleId IdType="pmc">PMC5063034</ArticleId>
            <ArticleId IdType="pubmed">27737834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG vaccine for COVID-19: first verdict and future directions. Front. Immunol. 2021;12:632478–632478. doi: 10.3389/fimmu.2021.632478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.632478</ArticleId>
            <ArticleId IdType="pmc">PMC7982405</ArticleId>
            <ArticleId IdType="pubmed">33763077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathurin KS, Martens GW, Kornfeld H, Welsh RM. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J. Virol. 2009;83:3528–3539. doi: 10.1128/JVI.02393-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.02393-08</ArticleId>
            <ArticleId IdType="pmc">PMC2663272</ArticleId>
            <ArticleId IdType="pubmed">19193795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinnijenhuis J, et al.  Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J. Innate Immun. 2014;6:152–158. doi: 10.1159/000355628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000355628</ArticleId>
            <ArticleId IdType="pmc">PMC3944069</ArticleId>
            <ArticleId IdType="pubmed">24192057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinnijenhuis J, et al.  Bacille calmette-guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA. 2012;109:17537–17542. doi: 10.1073/pnas.1202870109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1202870109</ArticleId>
            <ArticleId IdType="pmc">PMC3491454</ArticleId>
            <ArticleId IdType="pubmed">22988082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinnijenhuis J, et al.  BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin. Immunol. 2014;155:213–219. doi: 10.1016/j.clim.2014.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2014.10.005</ArticleId>
            <ArticleId IdType="pmc">PMC5084088</ArticleId>
            <ArticleId IdType="pubmed">25451159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander activation of CD8+ T cells contributes to the rapid production of IFN-γ in response to bacterial pathogens. J. Immunol. 2001;166:1097–1105. doi: 10.4049/jimmunol.166.2.1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.166.2.1097</ArticleId>
            <ArticleId IdType="pubmed">11145690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Netea MG, et al.  Trained immunity: a program of innate immune memory in health and disease. Science. 2016 doi: 10.1126/science.aaf1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaf1098</ArticleId>
            <ArticleId IdType="pmc">PMC5240844</ArticleId>
            <ArticleId IdType="pubmed">27126040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haahr S, et al.  Non-specific effects of BCG vaccination on morbidity among children in Greenland: a population-based cohort study. Int. J. Epidemiol. 2016;45:2122–2130. doi: 10.1093/ije/dyw244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ije/dyw244</ArticleId>
            <ArticleId IdType="pubmed">28338723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stensballe LG, et al.  BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial. Arch. Dis. Childhood. 2016 doi: 10.1136/archdischild-2016-310760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/archdischild-2016-310760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayaraman K, et al.  Two randomized trials of the effect of the Russian strain of Bacillus Calmette-Guerin alone or with oral polio vaccine on neonatal mortality in infants weighing &lt;2000 g in India. Pediatr. Infect. Dis. J. 2019;38:198–202. doi: 10.1097/inf.0000000000002198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000002198</ArticleId>
            <ArticleId IdType="pubmed">30256314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrington CP, et al.  Epidemiological studies of the non-specific effects of vaccines: II—methodological issues in the design and analysis of cohort studies. Trop. Med. Int. Health TM IH. 2009;14:977–985. doi: 10.1111/j.1365-3156.2009.02302.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-3156.2009.02302.x</ArticleId>
            <ArticleId IdType="pubmed">19531116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health, O. Meeting of the strategic advisory group of experts on immunization, April 2014—conclusions and recommendations. Weekly Epidemiol. Rec. Relevé Épidémiologique Hebdomadaire89, 221-236 (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Raabe VN, Shane AL. Group B streptococcus (Streptococcus agalactiae) Microbiol. Spect. 2019;7:7. doi: 10.1128/microbiolspec.GPP3-0007-2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/microbiolspec.GPP3-0007-2018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odutola A, et al.  Staphylococcus aureus bacteremia in children of rural areas of The Gambia, 2008–2015. Emerg. Infect. Dis. 2019;25:701. doi: 10.3201/eid2504.180935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2504.180935</ArticleId>
            <ArticleId IdType="pmc">PMC6433015</ArticleId>
            <ArticleId IdType="pubmed">30882307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalil IA, et al.  Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990–2016. Lancet Infect. Dis. 2018;18:1229–1240. doi: 10.1016/S1473-3099(18)30475-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(18)30475-4</ArticleId>
            <ArticleId IdType="pmc">PMC6202441</ArticleId>
            <ArticleId IdType="pubmed">30266330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marangu D, Zar HJ. Childhood pneumonia in low-and-middle-income countries: an update. Paediat. Resp. Rev. 2019;32:3–9.</Citation>
        </Reference>
        <Reference>
          <Citation>van Belkum A, et al.  Reclassification of Staphylococcus aureus nasal carriage types. J. Infect. Dis. 2009;199:1820–1826. doi: 10.1086/599119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/599119</ArticleId>
            <ArticleId IdType="pubmed">19419332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher HA, et al.  Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. Clin. Vaccine Immunol. 2013;20:1683–1689. doi: 10.1128/CVI.00427-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00427-13</ArticleId>
            <ArticleId IdType="pmc">PMC3837779</ArticleId>
            <ArticleId IdType="pubmed">23986316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McShane H, et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 2004;10:1240–1244. doi: 10.1038/nm1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1128</ArticleId>
            <ArticleId IdType="pubmed">15502839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanner R, et al.  Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. J. Immunol. Methods. 2019 doi: 10.1016/j.jim.2019.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jim.2019.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC7926177</ArticleId>
            <ArticleId IdType="pubmed">30710562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanner R, et al.  Tools for assessing the protective efficacy of TB vaccines in humans: in vitro Mycobacterial growth inhibition predicts outcome of in vivo Mycobacterial infection. Front. Immunol. 2020;10:2983. doi: 10.3389/fimmu.2019.02983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02983</ArticleId>
            <ArticleId IdType="pmc">PMC6968127</ArticleId>
            <ArticleId IdType="pubmed">31998295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanner R, et al.  Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. J. Immunol. Methods. 2019;469:1–10. doi: 10.1016/j.jim.2019.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jim.2019.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC7926177</ArticleId>
            <ArticleId IdType="pubmed">30710562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bekkering S, et al.  In vitro experimental model of trained innate immunity in human primary monocytes. Clin. Vaccine Immunol. 2016;23:926–933. doi: 10.1128/cvi.00349-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/cvi.00349-16</ArticleId>
            <ArticleId IdType="pmc">PMC5139603</ArticleId>
            <ArticleId IdType="pubmed">27733422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanner R, et al.  The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays. Sci. Rep. 2017;7:43478. doi: 10.1038/srep43478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep43478</ArticleId>
            <ArticleId IdType="pmc">PMC5335253</ArticleId>
            <ArticleId IdType="pubmed">28256545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moorlag S, et al.  BCG vaccination induces long-term functional reprogramming of human neutrophils. Cell Rep. 2020;33:108387. doi: 10.1016/j.celrep.2020.108387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.108387</ArticleId>
            <ArticleId IdType="pmc">PMC7672522</ArticleId>
            <ArticleId IdType="pubmed">33207187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss DW, Bonhag RS, Parks JA. Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG): I. Antimicrobial protection. J. Exp. Med. 1964;119:53–70. doi: 10.1084/jem.119.1.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.119.1.53</ArticleId>
            <ArticleId IdType="pmc">PMC2137800</ArticleId>
            <ArticleId IdType="pubmed">14113115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freyne B, et al.  Neonatal BCG vaccination influences cytokine responses to toll-like receptor ligands and heterologous antigens. J. Infect. Dis. 2018;217:1798–1808. doi: 10.1093/infdis/jiy069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiy069</ArticleId>
            <ArticleId IdType="pubmed">29415180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul-Clark MJ, et al.  Differential effects of gram-positive versus gram-negative bacteria on NOSII and TNFalpha in macrophages: role of TLRs in synergy between the two. Br. J. Pharmacol. 2006;148:1067–1075. doi: 10.1038/sj.bjp.0706815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0706815</ArticleId>
            <ArticleId IdType="pmc">PMC1752017</ArticleId>
            <ArticleId IdType="pubmed">16783405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snäll J, et al.  Differential neutrophil responses to bacterial stimuli: Streptococcal strains are potent inducers of heparin-binding protein and resistin-release. Sci. Rep. 2016;6:21288. doi: 10.1038/srep21288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep21288</ArticleId>
            <ArticleId IdType="pmc">PMC4758080</ArticleId>
            <ArticleId IdType="pubmed">26887258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth A, et al.  Low birth weight infants and calmette-guérin bacillus vaccination at birth: community study from guinea-bissau. Pediat. Infect. Dis. J. 2004;23:544–550. doi: 10.1097/01.inf.0000129693.81082.a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.inf.0000129693.81082.a0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black GF, et al.  BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet. 2002;359:1393–1401. doi: 10.1016/S0140-6736(02)08353-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(02)08353-8</ArticleId>
            <ArticleId IdType="pubmed">11978337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosa AI. Rescuing immunosenescence via non-specific vaccination. Immunology. 2021;1:231–239.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakr A, Brégeon F, Mège J-L, Rolain J-M, Blin O. Staphylococcus aureus nasal colonization: an update on mechanisms, epidemiology, risk factors, and subsequent infections. Front. Microbiol. 2018;9:2419–2419. doi: 10.3389/fmicb.2018.02419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2018.02419</ArticleId>
            <ArticleId IdType="pmc">PMC6186810</ArticleId>
            <ArticleId IdType="pubmed">30349525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>den Heijer CDJ, et al.  Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S. aureus, in nine European countries: a cross-sectional study. Lancet Infect. Dis. 2013;13:409–415. doi: 10.1016/S1473-3099(13)70036-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(13)70036-7</ArticleId>
            <ArticleId IdType="pubmed">23473661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nouwen JL, et al.  Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a “culture rule”. Clin. Infect. Dis. 2004;39:806–811. doi: 10.1086/423376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/423376</ArticleId>
            <ArticleId IdType="pubmed">15472812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denis O. Route of transmission of Staphylococcus aureus. Lancet Infect. Dis. 2017;17:124–125. doi: 10.1016/S1473-3099(16)30512-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(16)30512-6</ArticleId>
            <ArticleId IdType="pubmed">27863960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rigby KM, DeLeo FR. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin. Immunopathol. 2012;34:237–259. doi: 10.1007/s00281-011-0295-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-011-0295-3</ArticleId>
            <ArticleId IdType="pmc">PMC3271231</ArticleId>
            <ArticleId IdType="pubmed">22080185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N. Engl. J. Med. 2001;344:11–16. doi: 10.1056/nejm200101043440102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejm200101043440102</ArticleId>
            <ArticleId IdType="pubmed">11136954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghasemzadeh-Moghaddam H, et al.  Nasal carriers are more likely to acquire exogenous &lt;em&gt;Staphylococcus aureus&lt;/em&gt; strains than non-carriers. Clin. Microbiol. Infect. 2015;21(998):e991–998.e997. doi: 10.1016/j.cmi.2015.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2015.07.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole AM, et al.  Determinants of Staphylococcus aureus nasal carriage. Clin. Diagn. Lab. Immunol. 2001;8:1064–1069. doi: 10.1128/cdli.8.6.1064-1069.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/cdli.8.6.1064-1069.2001</ArticleId>
            <ArticleId IdType="pmc">PMC96227</ArticleId>
            <ArticleId IdType="pubmed">11687441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanger P, et al.  Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human beta-defensin 3 but not human beta-defensin 2. Infect. Immun. 2010;78:3112–3117. doi: 10.1128/iai.00078-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.00078-10</ArticleId>
            <ArticleId IdType="pmc">PMC2897370</ArticleId>
            <ArticleId IdType="pubmed">20404083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Midorikawa K, et al.  Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect. Immun. 2003;71:3730–3739. doi: 10.1128/iai.71.7.3730-3739.2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.71.7.3730-3739.2003</ArticleId>
            <ArticleId IdType="pmc">PMC162002</ArticleId>
            <ArticleId IdType="pubmed">12819054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frickmann H, et al.  Influence of broth enrichment as well as storage and transport time on the sensitivity of MRSA surveillance in the tropics. Eur. J. Microbiol. Immunol. 2017;7:274–277. doi: 10.1556/1886.2017.00028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1556/1886.2017.00028</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
